Stoke Therapeutics, Inc.STOKNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+20.2%
5Y CAGR+31.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+20.2%/yr
vs +73.9%/yr prior
5Y CAGR
+31.8%/yr
Recent deceleration
Acceleration
-53.6pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
4x
Strong expansion
Streak
8 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$202.97M+47.2%
2024$137.93M+11.6%
2023$123.55M+5.8%
2022$116.76M+35.7%
2021$86.06M+68.4%
2020$51.12M+45.1%
2019$35.23M+175.6%
2018$12.78M+130.1%
2017$5.55M-